38 results
8-K
EX-1.1
AQST
Aquestive Therapeutics Inc
21 Mar 24
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
4:06pm
expenses incident to the performance of its obligations under this Agreement, including (i) the preparation, printing and filing of the Registration … such consultants, and the cost of aircraft and other transportation chartered in connection with the road show, (viii) the filing fees incident
8-K
EX-10.2
AQST
Aquestive Therapeutics Inc
2 Nov 23
Aquestive Therapeutics Completes $45 Million Debt Refinancing
8:45am
with customary opinion practice (and each such legal opinion shall cover such other matters incident to the transactions contemplated
424B3
AQST
Aquestive Therapeutics Inc
2 Oct 23
Prospectus supplement
4:18pm
certain fees and expenses incurred by the Company incident to the registration of the Warrant Shares. The Company has agreed to indemnify the Selling
8-K
EX-10.1
b3ph1t
8 Jun 22
Aquestive Therapeutics, Inc. Announces $8.5 Million Registered Direct Offering
4:22pm
8-K
EX-1.1
tpqi5
8 Jun 22
Aquestive Therapeutics, Inc. Announces $8.5 Million Registered Direct Offering
4:22pm
424B5
bv61uy7nty2ko5cv0
13 Apr 22
Prospectus supplement for primary offering
8:00am
8-K
EX-1.1
mvbyvuux
16 Dec 19
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
5:26pm
424B5
0mgq lpkw
17 Sep 19
Prospectus supplement for primary offering
5:13pm
S-3
EX-1.2
l8hnohtvggvwz5e468s
11 Sep 19
Shelf registration
5:21pm
S-3
bkkilz
11 Sep 19
Shelf registration
5:21pm
8-K
EX-10.2
rs468 rz35ly
16 Jul 19
Aquestive Therapeutics Completes $70 Million Debt Refinancing
12:00am